Immunotherapy Comes of Age in Lung Cancer

Clinical Lung Cancer

Volumn 18, Issue 1, 2017, Pages 13-22

  Khanna, Priyanka ^a   Blais, Normand ^b   Gaudreau, Pierre Olivier ^b   Corrales Rodriguez, Luis ^c  

^a Department of Oncology   (Costa Rica)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Centro de Investigación y Manejo del Cáncer CIMCA   (Costa Rica)

Author keywords

Immune checkpoints; NSCLC; PD 1; PD L1; SCLC

Indexed keywords

BCG VACCINE; BELAGENPUMATUCEL L; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA UROGASTRONE; IMMUNE CHECKPOINT REGULATOR; IMMUNOLOGIC AGENT; MELANOMA ANTIGEN 3; MITUMOMAB; RACOTUMOMAB; TECEMOTIDE; TERGENPUMATUCEL L; TG 4010; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

AGE; ANTIGEN SPECIFIC IMMUNOTHERAPY; CANCER IMMUNOEDITING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGNOSIS;

EID: 85007565534     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.06.006     Document Type: Review

References (99)

1. 1 Howlander, N., Noone, A.M., Krapcho, M., et al. (eds.) SEER Cancer Statistics Review, 1975-2012, 2014, National Cancer Institute, Bethesda.
2. 2 Thomas, A., Liu, S.V., Subramaniam, D.S., Giaccone, G., Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 12 (2015), 511–526.
3. 3 Siegel, R., Ma, J., Zou, Z., Jemai, A., Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
4. 4 Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N Engl J Med 359 (2008), 1367–1380.
5. 5 Villaruz, L.C., Kalyan, A., Zarour, H., Socinski, M.A., Immunotherapy in lung cancer. Transl Lung Cancer Res 3 (2014), 2–14.
6. 6 Bobbio, A., Alifano, M., Immune therapy of non-small cell lung cancer: the future. Pharmacol Res 99 (2015), 217–222.
7. 7 Tucker, Z.C., Laguna, B.A., Moon, E., Singhal, S., Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 38 (2012), 650–661.
8. 8 Aupérin, A., Le Péchoux, C., Rolland, E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
9. 9 Travis, W.D., Brambilla, E., Riely, G.J., New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31 (2013), 992–1001.
10. 10 Méry, B., Guy, J.B., Swalduz, A., et al. The evolving locally-advanced non-small cell lung cancer landscape: building on past evidence and experience. Crit Rev Oncol Hematol 96 (2015), 319–327.
11. 11 Leighl, N., Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 66 (2012), S52–S58.
12. 12 Kimura, H., Matsui, Y., Ishiwaka, A., Nakajima, T., Yoshina, M., Sakairi, Y., Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother 64 (2015), 51–59.
13. 13 Teixidó, C., Karachaliou, N., González-Cao, M., Morales-Espinosa, D., Rosell, R., Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 12 (2015), 87–95.
14. 14 Sundar, R., Soong, R., Cho, B.-C., Brahmer, J.R., Soo, R.A., Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85 (2014), 101–109.
15. 15 Anagnostou, V.K., Brahmer, J.R., Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 21 (2015), 976–984.
16. 16 Karachaliou, N., Gonzalez Cao, M., Teixidó, C., et al. Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biol Med 12 (2015), 79–86.
17. 17 Rice, S.J., Miller, B., Wagman, M., Jamorabo, D.S., Liu, X., Belani, C.P., Clinical approaches to immunotherapy in non-small cell lung cancer: current and future perspectives. Curr Mol Pharmacol 8 (2015), 1–13.
18. 18 Ruffini, E., Asioli, S., Filosso, P.L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 87 (2009), 365–372.
19. 19 Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004), 329–360.
20. 20 Vesely, M.D., Kershaw, M.H., Schrieber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29 (2011), 235–271.
21. 21 Swann, J.B., Smyth, M.J., Immune surveillance of tumors. J Clin Invest 117 (2007), 1137–1146.
22. 22 Forde, P.M., Reiss, K.A., Zeidan, A.M., Brahmer, J.R., What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 18 (2013), 1203–1213.
23. 23 Harvey, R.D., Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther 96 (2014), 214–223.
24. 24 Tarhini, A.A., Iqbal, F., CTLA-4 blockade: therapeutic potential in cancer treatments. Oncol Targets Ther 3 (2010), 15–25.
25. 25 Johnson, D.B., Rioth, M.J., Horn, L., Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 15 (2014), 658–669.
26. 26 Raval, R.R., Sharabi, A.B., Walker, A.J., et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer, 2, 2014, 14.
27. 27 Homet Moreno, B., Ribas, A., Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 112 (2015), 1421–1427.
28. 28 Shin, D.R., Ribas, A., The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Immunol 33 (2015), 23–35.
29. 29 Aerts, J.G., Hegmans, J.P., Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 73 (2013), 2381–2388.
30. 30 Shih, K., Arkenau, H.T., Infante, J.R., Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74 (2014), 1993–2013.
31. 31 Sanlorenzo, M., Vujic, I., Daud, A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151 (2015), 1206–1212.
32. 32 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
33. 33 Khalil, D.N., Budhu, S., Gasmi, B., et al. The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy. Adv Cancer Res 128 (2015), 1–68.
34. 34 Xu, M., Xie, Y., Ni, S., Liu, H., The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med, 3, 2015, 96.
35. 35 Shepherd, F.A., Douillard, J.Y., Blumenschein, G.R. Jr., Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 6 (2011), 1763–1773.
36. 36 Kono, K., Current status of cancer immunotherapy. J Stem Cells Regen Med 10 (2014), 8–13.
37. 37 Lynch, T.J., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30 (2012), 2046–2054.
38. 38 Mostafa, A.A., Morris, D.G., Immunotherapy for lung cancer: has it finally arrived?. Front Oncol, 4, 2014, 288.
39. 39 Langer, C.J., Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 38 (2015), 422–430.
40. 40 Declerck, S., Vansteenkiste, J., Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol 10 (2014), 91–105.
41. 41 Scagliotti, G.V., Bironzo, P., Vansteenkiste, J.F., Addressing the unmet need in lung cancer: the potential of immuno-oncology. Cancer Treat Rev 41 (2015), 465–475.
42. 42 Yoon, S.H., Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) 77 (2014), 111–115.
43. 43 Zatloukal, P., Heo, D.S., Park, K., et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 27(suppl), 2009 15S, abstract 8071.
44. 44 Lu, J., Lee-Gabel, L., Nadeau, M.C., Ferencz, T.M., Soefje, S.A., Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 21 (2015), 451–467.
45. 45 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
46. 46 Dasanu, C.A., Sethi, N., Ahmed, N., Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 12 (2012), 923–937.
47. 47 Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
48. 48 Vasekar, M., Liu, X., Zheng, H., Belani, C.P., Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 5 (2014), 39–47.
49. 49 Konishi, J., Yamazaki, K., Azumi, M., Kinoshita, I., Dosaka-Akita, H., Nishimura, M., B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10 (2004), 5094–5100.
50. 50 Chen, Y.B., Mu, C.Y., Huang, J.A., Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98 (2012), 751–755.
51. 51 Mahoney, K.M., Atkins, M.B., Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28:suppl 3 (2014), 39–48.
52. 52 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
53. 53 Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
54. 54 Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24 (2012), 207–212.
55. 55 Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. World Congress on Lung Cancer, 2015, Denver, CO.
56. 56 Antonia SJ, Grosso JF, Horak CE, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (anti-PD-1, BMS-936558; ONO-4538). World Congress on Lung Cancer, 2015, Denver, CO.
57. 57 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
58. 58 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
59. 59 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
60. 60 Rizvi N, Getting S, Goldman J. Safety and efficacy of first-line nivolumab and ipilimumab in non-small cell lung cancer. 16th World Conference on Lung Cancer, 2015, Denver, CO.
61. 61 Callahan, M.K., Postow, M.A., Wolchok, J.D., CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol, 4, 2015, 385.
62. 62 Sundar, R., Cho, B.-C., Brahmer, J.R., Soo, R.A., Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 7 (2015), 85–96.
63. 63 Barbee, M.S., Ogunniyi, A., Horvat, T.Z., Dang, T.O., Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 49 (2015), 907–937.
64. 64 Pembrolizumab shows promise for NSCLC. Cancer Discov, 5, 2015, 572.
65. 65 Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). World Conference on Lung Cancer, 2015, Denver, CO.
66. 66 Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
67. 67 Ott PA, Elez E, Hiret S, et al. Pembrolizumab for ED SCLC: efficacy and relationship with PD-L1 expression. World Congress on Lung Cancer, 2015, Denver, CO.
68. 68 Ott, P.A.E., Fernandez, M.E.E., Hiret, S., et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol, 33(suppl), 2015 abstract 7502.
69. 69 Herbst, R.S., Baas, P., Kim, D.-W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
70. 70 Goldberg SB, Gettinger SN, Mahajan A, et al. A phase II trial of pembrolizumab for untreated brain metastases from non-small cell lung cancer. World Congress on Lung Cancer, 2015, Denver, CO.
71. 71 Velcheti, V., Schalper, K.A., Carvajal, D.E., et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94 (2014), 107–116.
72. 72 Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a phase Ib safety and efficacy update. World Conference on Lung Cancer, 2015, Denver, CO.
73. 73 Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
74. 74 Bradbury, P.A., Shepherd, F.A., Immunotherapy for lung cancer. J Thorac Oncol 3:6 suppl 2 (2008), S164–S170.
75. 75 Drake, C.G., Lipson, E.G., Brahmer, J.R., Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 11 (2014), 24–37.
76. 76 Yang, X.-N., Huang, L., Chen, Y., et al. Single nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC). Chin J Cancer Res 27 (2015), 301–308.
77. 77 Domagala-Kulawik, J., The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res 4 (2015), 177–190.
78. 78 Vansteenkiste, J., Zielinski, M., Linder, A., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31 (2013), 2396–2403.
79. 79 Gure, A.O., Chua, R., Williamson, B., et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11 (2005), 8055–8062.
80. 80 Kim, S.H., Lee, S., Lee, C.H., et al. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 187 (2009), 401–411.
81. 81 Ulloa-Montoya, F., Louahed, J., Dizier, B., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31 (2013), 2388–2395.
82. 82 Tyagi, P., Mirakhur, B., MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10 (2009), 371–374.
83. 83 GlaxoSmithKline press release. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. April 2014. Available at http://us.gsk.com/en-us/media/press-releases/2014/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer. Accessed: July 14, 2016.
84. 84 Thomas, A., Hassan, R., Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13 (2012), e301–e310.
85. 85 Freeman-Keller, M., Goldman, J., Gray, J., Vaccine immunotherapy in lung cancer: clinical experience and future directions. Pharmacol Ther 153 (2015), 1–9.
86. 86 Butts, C., Maksymiuk, A., Goss, G., et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137 (2011), 1337–1342.
87. 87 Butts, C., Socinski, M.A., Mitchell, P.L., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15 (2014), 59–68.
88. 88 Ramlau, R., Quoix, E., Rolski, J., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 3 (2008), 735–744.
89. 89 Quoix, E., Ramlau, R., Westeel, V., et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12 (2011), 1125–1133.
90. 90 Gonzalez, G., Crombet, T., Torres, F., et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14 (2003), 461–466.
91. 91 Gonzalez Marinello, G.M., Santos, E.S., Raez, L.E., Epidermal growth factor vaccine in non-small-cell lung cancer. Expert Rev Anticancer Ther 12 (2012), 439–445.
92. 92 Neninger Vinageras, E., de la Torre, A., Osorio Rodriguez, M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26 (2008), 1452–1458.
93. 93 Rodriguez, P.C., Rodriguez, G., González, G., Lage, A., Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 12 (2010), 17–23.
94. 94 Neninger, E., Verdecia, B.G., Crombet, T., et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother 32 (2009), 92–99.
95. 95 Rodriguez, P.C., Neninger, E., Garcia, B., et al. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines, 9, 2011, 7.
96. 96 Giaccone, G., Debruyne, C., Felip, E., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guérin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23 (2005), 6854–6864.
97. 97 Alfonso, S., Valdés-Zayas, A., Santiesteban, E.R., et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20 (2014), 3660–3671.
98. 98 Bierie, B., Moses, H.L., TGF-beta and cancer. Cytokine Growth Factor Rev 17 (2006), 29–40.
99. 99 Nemunaitis, J., Nemunaitis, M., Senzer, N., et al. Phase II trial of belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16 (2009), 620–624.